Eli Lilly and CompanyvsUltragenyx Pharmaceutical

LLY and RARE stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,347.11

Value $1.27T

-0.30%
LLY's page

RARE

Ultragenyx Pharmaceutical Inc.

$16.48

Value $1.7B

-4.30%
RARE's page

Eli Lilly and Company (LLY) has a market value of $1.27T and Ultragenyx Pharmaceutical (RARE) $1.7B. Over the last year, with dividends, LLY moved +29.1% and RARE -48.3%. Dividend yield: LLY 0.47%, RARE none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.27T

    RARE$1.7B

    LLY is 757 times RARE

  • Revenue, 12 months

    LLY$86.5B

    RARE$730M

    LLY is 118 times RARE

  • Net income, 12 months

    LLY$27.6B

    RARE-$524M

  • Operating margin

    LLY–

    RARE-64.0%

  • ROIC

    LLY35.5%

    RARE–

  • P/E

    LLY46.1

    RARE–

  • Dividend yield

    LLY0.5%

    RARE0.0%

    0.5 points apart

  • 5-year return

    LLY+439.5%

    RARE-79.2%

    518.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+439.5%

RARE-79.2%

020040060020222023202420252026
Returns by period
PeriodLLYWith dividendsRAREWith dividends
1 year since November 19, 2025+29.1%Price +28.3%-48.3%Price -48.3%
3 years since November 20, 2023+130.0%+32.0% a yearPrice +125.4%-58.1%-25.2% a yearPrice -58.1%
5 years since November 19, 2021+439.5%+40.1% a yearPrice +416.7%-79.2%-27.0% a yearPrice -79.2%
10 years since November 21, 2016+1,944.6%+35.2% a yearPrice +1,657.7%-80.5%-15.1% a yearPrice -80.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyRAREUltragenyx Pharmaceutical

Valuation

LLYRARE
Valuation
Price$1,347.11$16.48
Market value$1.27T$1.7B
Enterprise value (EV)$1.32T$1.4B
P/E46.1–
P/E, 5-year median49.9–
P/B31.6–
EV/EBIT37.8–
Free cash flow yield1.6%–

Results and growth

LLYRARE
Results and growth
Revenue, 12 months$86.5B$730M
Net income, 12 months$27.6B-$524M
Free cash flow, 12 months$19.7B-$442M
Earnings per share, 12 months$30.81-$5.18
Revenue growth, year on year44.7%20.2%
Revenue growth a year, past+21.6%over 5 years+20.0%over 5 years
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYRARE
Margins and returns on capital
Gross margin83.6%–
Operating margin–-64.0%
Net margin31.9%-71.8%
ROIC35.5%–
ROE88.6%–

Balance sheet

LLYRARE
Balance sheet
Cash$4.9B$266M
Total debt$49.5B$36M
Net debt / EBITDA1.2–
Interest cover38.9×–

Dividends and buybacks

LLYRARE
Dividends and buybacks
Dividend yield0.5%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%–
Shareholder yield0.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or RARE

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or Ultragenyx Pharmaceutical?

By market value, Eli Lilly and Company ($1.27T) is about 756.6 times Ultragenyx Pharmaceutical ($1.7B), at today's prices.

How did LLY and RARE stock do over the last 10 years?

Since November 21, 2016, LLY's price moved +1,657.7% and RARE's -80.5%. With dividends: LLY +1,944.6% (+35.2% a year), RARE -80.5% (-15.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or RARE?

The dividend yield at today's price is 0.47% for Eli Lilly and Company and none for Ultragenyx Pharmaceutical. Over the last twelve months they paid $6.34 and – per share.

Which has the higher profit margins, Eli Lilly and Company or Ultragenyx Pharmaceutical?

Over the last twelve months, the net margin was 31.9% for Eli Lilly and Company and -71.8% for Ultragenyx Pharmaceutical, and the operating margin – and -64.0%. Revenue was $86.5B and $730M.

Which is the better investment, Eli Lilly and Company or Ultragenyx Pharmaceutical?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.